［1］   Randall ME，Filiaci VL，Muss H，et al．Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study［J］．J Clin Oncol，2006，24（1）：36-44．

［2］   Nakayama K，Nagai Y，Ishikawa M，et al． Concomitant postoperative radiation and chemotherapy following surgery was associated with improved overall survival in patients with FIGO stages III and IV endometrial cancer［J］．Int J Clin Oncol，2010，15（5）：440-446．

［3］   Hogberg T，Signorelli M，de Oliveira CF，et al．Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies［J］．Eur J Cancer，2010，46（13）：2422-2431

［4］   Lupe K, D'Souza DP, Kwon JS，et al.Adjuvant carboplatin and paclitaxel chemotherapy interposed with involved field radiation for advanced endometrial cancer［J］.Gynecol Oncol，2009，114（1）：94-98

［5］   Fowler JM, Brady WE, Grigsby PW，et al.Sequential chemotherapy and irradiation in advanced stage endometrial cancer:a Gynecologic Oncology Group phase Ⅰtrial of doxorubicin–cisplatin followed by whole abdomen irradiation［J］.Gynecol Oncol，2009，112（3）：553-557.

［6］   Secord AA, Havrilesky LJ, O'Malley DM,et al．A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer［J］．Gynecol Oncol，2009，114（3）：442-447．

［7］   Geller MA，Ivy J，Dusenbery KE，et al．A single institution experience using sequential multi-modality adjuvant chemotherapy and radiation in the "sandwich" method for high risk endometrial carcinoma［J］．Gynecol Oncol，2010，118（1）：19-23．

［8］   Vandenput I，Van Calster B，Capoen A ，et al．Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage Ⅳ): a new preferred treatment［J］．Br J Cancer，2009，101（2）：244-249

［9］   李卓永，梁宇闯，林坚，等．子宫动脉化疗栓塞治疗中晚期子宫内膜癌［J］．中国介入影像与治疗学，2005，2( 2) : 124-126.

［10］   Slomovitz BM，Lu KH，Johnston T，et al.A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma［J］.Cancer，2010，116(23):5415-5419.

［11］    Oza AM，Elit L，Tsao MS，et al.Phase Ⅱ study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group［J］.J Clin Oncol，2011，29 （24）：3278-3285.

［12］    Villella JA，Cohen S，Smith DH，et al．HER-2/ neu overexpression in uterine papillary serous cancers and its possible therapeutic implications［J］．Int J Gynecol Cancer，2006，16（5）：1897-1902．

［13］   Aghajanian C, Sill MW, Darcy KM, et al.Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study［J］.J Clin Oncol，2011,29(16):2259-2265.

［14］   Moxley KM, McMeekin DS.Endometrial carcinoma: a review of chemotherapy, drug resistance, and the search for new agents［J］.Oncologist，2010，15(10):1026-1033.

［15］   Nishio S, Koyanagi T, Miyabe K,et al.Two cases of multidrug-resistant recurrent endometrial cancer successfully treated with medroxyprogesterone acetate (MPA) ［J］.Gan To Kagaku Ryoho，2010,37(4):735-738.

［16］   Akizuki S, Katsumata N, Yamanaka Y, et al.Weekly paclitaxel in patients with CAP-resistant advanced or recurrent endometrial carcinoma: a series of four patients［J］.Int J Clin Oncol，2005，10(4):272-275.

（2014-11-30收稿）